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Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From
the Heart “OMics” in AGEing (HOMAGE) Study
Lotte Jacobs, PhD;* Ljupcho Efremov, MD;* Jo~ao Pedro Ferreira, MD, PhD; Lutgarde Thijs, MSc; Wen-Yi Yang, MD; Zhen-Yu Zhang, MD;
Roberto Latini, MD, PhD; Serge Masson, PhD; Nera Agabiti, MD; Peter Sever, MD, PhD; Christian Delles, MD, PhD; Naveed Sattar, MD,
PhD; Javed Butler, MD, PhD; John G. F. Cleland, MD, PhD; Tatiana Kuznetsova, MD, PhD; Jan A. Staessen, MD, PhD; Faiez Zannad, MD, PhD;
On behalf of the Heart “OMics” in AGEing (HOMAGE) investigators**
Background-—To address the need for personalized prevention, we conducted a subject-level meta-analysis within the framework
of the Heart “OMics” in AGEing (HOMAGE) study to develop a risk prediction model for heart failure (HF) based on routinely
available clinical measurements.
Methods and Results-—Three studies with elderly persons (Health Aging and Body Composition [Health ABC], Valutazione della
PREvalenza di DIsfunzione Cardiaca asinTOmatica e di scompenso cardiaco [PREDICTOR], and Prospective Study of Pravastatin in
the Elderly at Risk [PROSPER]) were included to develop the HF risk function, while a fourth study (Anglo-Scandinavian Cardiac
Outcomes Trial [ASCOT]) was used as a validation cohort. Time-to-event analysis was conducted using the Cox proportional
hazard model. Incident HF was deﬁned as HF hospitalization. The Cox regression model was evaluated for its discriminatory
performance (area under the receiver operating characteristic curve) and calibration (Grønnesby-Borgan v2 statistic). During a
follow-up of 3.5 years, 470 of 10 236 elderly persons (mean age, 74.5 years; 51.3% women) developed HF. Higher age, BMI,
systolic blood pressure, heart rate, serum creatinine, smoking, diabetes mellitus, history of coronary artery disease, and use of
antihypertensive medication were associated with increased HF risk. The area under the receiver operating characteristic curve
of the model was 0.71, with a good calibration (v2 7.9, P=0.54). A web-based calculator was developed to allow easy
calculations of the HF risk.
Conclusions-—Simple measurements allow reliable estimation of the short-term HF risk in populations and patients. The risk model
may aid in risk stratiﬁcation and future HF prevention strategies. ( J Am Heart Assoc. 2017;6:e005231. DOI: 10.1161/JAHA.
116.005231.)
Key Words: heart failure • meta-analysis • risk factor • risk prediction
H eart failure (HF) is a complex syndrome often charac-terized by an abnormal cardiac structure and function
leading to diminished quality of life, recurrent and costly
hospital admissions, and premature death.1 HF remains a
major public health concern because of the ageing of the
populations and the increasing prevalence of HF-associated
comorbidities such as diabetes mellitus and obesity.2 The
estimated prevalence of HF amounts to 1% to 2% of the adult
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population in developed countries, with the prevalence rising
to >10% in those 70 years and older. The incidence is 5 to
10 per 1000 person-years.3 Remarkable therapeutic
advances in the past decades entailed a 3-fold decrease
in fatal HF, thereby increasing its prevalence and incidence.
However, these advances are limited to HF with reduced
ejection fraction, while its counterpart, HF with preserved
ejection fraction, representing 50% of all HF cases, still lacks
speciﬁc therapeutic strategies other than treating risk
factors.4
Given the overall magnitude and lack of speciﬁc treatment
for >50% of cases, identifying individuals at high risk for HF
remains a priority in clinical research. Early identiﬁcation will
potentially allow testing preventive strategies in at-risk
populations thereby delaying or preventing HF onset and
subsequently the disease burden. In this regard, a well-
calibrated, easily applicable, and generalizable risk model will
help clinicians and trialists identify “high-risk” patients. The
former should concentrate on risk factor control with
potential to delay HF onset, while the latter must focus on
developing and testing novel therapeutic approaches.5 In this
study, we aimed to identify routinely measured risk factors
that reproducibly predict incident HF in an elderly population.
We developed an easy-to-use calculator, allowing estimation
of an individuals’ risk for incident HF in daily, routine clinical
practice. The Heart “OMics” in AGEing (HOMAGE) study6 was
used to conduct this subject-level meta-analysis and to
develop an adequate scoring model.
Methods
Heart “OMics” in AGEing Database
The HOMAGE study database is constructed and maintained
at the Studies Coordinating Centre in Leuven, Belgium. By
sending anonymized data, the contributing partners conﬁrmed
that their study complies with good clinical practice (Helsinki
Declaration), that all participants provided written informed
consent, and that at the time of its conduct the study
conformed to national regulations on clinical research in
humans and on the protection of privacy. A detailed
description of the database is available elsewhere.6 The
database used for this analysis was locked on January 16,
2016.
Cohorts Analyzed
The entire HOMAGE database consists of 21 studies
(n=46 134). Studies were eligible for inclusion in this analysis
if information was available on fatal and/or nonfatal HF, with
at least 20 events. We excluded 4 HF cohorts (n=4312), as
well as 9 studies (n=7565) without information on HF
outcome, and 4 studies with <20 HF events (n=4120).
Among the 4 included studies (n=30 137), persons with a
history of HF at baseline (n=223), those with missing
information on incident HF (n=144), or those lost to follow-
up (n=279) were excluded. Figure 1 gives a detailed overview
of the selection of the studies. Table 1 describes the 4
cohorts included in this analysis.
Description of cohorts
The Health Aging and Body Composition (Health ABC) study is
a cohort of 1584 women and 1491 men (aged ≥70 years),
randomly recruited among Medicare beneﬁciaries residing in
Pittsburg, Pennsylvania, and Memphis, Tennessee (April
1997–June 1998).7
The Valutazione della PREvalenza di DIsfunzione Cardiaca
asinTOmatica e di scompenso cardiaco (PREDICTOR) trial is a
population study of a random sample of 5940 people from the
Regional Population Registry of 4 Italian cities in the Lazio
region (June 2007–January 2010). A total of 2001 people
(33.7% of those invited), older than 65 years, provided written
informed consent and were referred to 8 cardiology centers
for clinical examination, blood tests, electrocardiography, and
echocardiography.8,9
Figure 1. Flow chart of studies and participants included in the
analysis. HF indicates heart failure.
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PROSPER (Prospective Study of Pravastatin in the Elderly
at Risk) is a randomized, double-blind, placebo-controlled trial
designed to test the hypothesis that treatment with pravas-
tatin compared with placebo would reduce the risk of
cardiovascular and cerebrovascular events in a cohort of
2000 women and 2804 men older than 70 years, with a
history of vascular disease or at high risk for developing
vascular disease. From 1997 until 1999, patients were
enrolled via 3 coordinating centers in Scotland, Ireland, and
The Netherlands.10,11
Validation cohort
ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) is a
prospective, randomized, open, blinded end point trial, which
recruited 19 257 high-risk hypertensive patients aged 40 to
80 years, in Scandinavian countries, the United Kingdom, and
Ireland (1998–2000).12,13
Deﬁnition of Events
Table 1 gives an overview of the deﬁnition of events within
each study. In all 3 studies, incident HF was deﬁned as HF
hospitalization. HF hospitalizations in the Health ABC study
were conﬁrmed by reviewing medical records of the partic-
ipants.14 In the PREDICTOR study, HF hospitalizations were
deﬁned by International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation code 428 as the main cause
of hospital admission. For the PROSPER trial, incident HF was
deﬁned as HF hospitalizations. Hospitalization records were
examined and deﬁned based on a combination of symptoms
and signs, including chest radiography with ﬂuid congestion or
echocardiogram with severely diminished left ventricular
function.15
Validation cohort
ASCOT deﬁned HF events based on clinical signs and
symptoms, chest x-rays and echocardiography, or diagnosis
of HF by the attending physician.
Statistical Analysis
For database management and statistical analyses, SAS
software version 9.3 (SAS Institute, Cary, NC, USA) was
used. Continuous variables were expressed as meanSD
and categorical variables as proportions. Missing values for
BMI, systolic blood pressure, diastolic blood pressure, heart
rate, glucose, cholesterol, and creatinine were imputated
from the regression slope on age after stratiﬁcation for
cohort and sex. For comparison of means and proportions,
the large sample Z-test and chi-square test were used,
respectively. Statistical signiﬁcance was a 2-sided P value of
<0.05.
Time-to-event analysis was conducted using the Cox
proportional hazard model. Follow-up time in the Health
ABC study was limited to the maximum follow-up time of the
other 2 included cohorts, ie, 5.5 years. Log-linearity was
checked by testing the functional forms of the covariable by
the Kolmogorov-type supremum test. Covariables were
entered into the multivariable model according to a stepwise
selection procedure with P values for covariables to enter and
stay in the model set to P=0.15 and P=0.05, respectively. Sex
and age were forced into all models and other covariables
considered to be of potential relevance and offered to the
Table 1. Description of Included Studies
Study Type of Patients Age Range, y
Total No.
(HF Events)
Median Follow-Up
(5th–95th Percentile) Deﬁnition of HF
Study population Health ABC Population-based
(elderly persons)
70.0–80.0 3075 (574) 12.1 (2.0–14.1) HF hospitalization:
confirmation by reviewing
hospital records
PREDICTOR Population-based
(elderly persons)
65.0–86.4 2001 (44) 3.9 (2.5–5.0) HF hospitalization: main
cause of hospital
admission=ICD-9-CM code
428
PROSPER Patients at high risk of
developing vascular
disease
70.0–83.4 5804 (234) 3.3 (1.4–3.8) HF hospitalization:
confirmation by reviewing
hospital records
External validation ASCOT Hypertensive patients 40.0–80.0 19 257 (292) 5.6 (3.5–6.6) HF hospitalization and
physician-based
diagnosis/HF death
ASCOT indicates Anglo-Scandinavian Cardiac Outcomes Trial; Health ABC, Health Aging and Body Composition; HF, heart failure; ICD-9-CM, International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation; PREDICTOR, Valutazione della PREvalenza di DIsfunzione Cardiaca asinTOmatica e di scompenso cardiac; PROSPER, Prospective Study of Pravastatin in the
Elderly at Risk.
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model were BMI, systolic and diastolic blood pressure, heart
rate, blood glucose, serum total, high-density lipoprotein and
low-density lipoprotein cholesterol, serum creatinine, smoking
and drinking, use of antihypertensive medication, and history
of diabetes mellitus, cardiovascular, coronary artery disease,
peripheral artery, and cerebrovascular disease. In a sensitivity
analysis, speciﬁc drug classes of antihypertensive treatment
were added to the Cox models. Antihypertensive drug classes
included b-blockers, inhibitors of the renin-angiotensin-
aldosterone system (RAAS), vasodilators, and diuretics. RAAS
inhibitors included angiotensin-converting enzyme inhibitors
and angiotensin II type 1 receptor blockers, while vasodilators
included calcium channel blockers and a-blockers. All models
were additionally adjusted for study.
Discrimination of the Cox regression models was
assessed by calculating the area under the receiver oper-
ating characteristic curve (AUC), through a method taking
into account time dependence and censoring, as previously
described by Chambles and Diao.16 Assessment of the
calibration, which demonstrates the goodness of ﬁt of the
models, was performed with the Grønnesby-Borgan v2
statistic. This test measures the level of agreement between
observed versus predicted number of events, which were
visually plotted across deciles of the predicted risk. SAS
macros developed in the ARIC (Atherosclerosis Risk in
Communities) study17 were used for these calculations. To
internally validate our models, 100 bootstrap samples were
generated, sampling subjects with replacement. We adjusted
our AUC obtained from the internal validation for optimism.
The external validation of our model was done in the ASCOT
cohort.
Risk calculator
The formula below was used to calculate the risk ðp^Þ:
p^ ¼ 1 S0ðtÞexp ð
Pq
i¼1 biwi;refÞ½ ð
Pp
i¼1 bi
XiÞ
 
where S0(t) is average survival at follow-up time t (t=5 years),
q is the number of continuous risk factors, p is the total
number of risk factors (continuous and categorical), bi is the
regression coefﬁcient of the i-th risk factor as estimated by
the Cox regression model, wi,ref is the reference value of the
base category of the i-th risk factor, Xi is the mean of the i-th
risk factor. We implemented this formula in Excel to develop
an easy-to-use risk calculator (Figure S1).
Results
Study Population
A study population of 10 236 elderly people (51.3% women)
with a mean ageSD of 74.53.7 years were included.
Mean BMISD was 26.94.4 kg/m2 (Table 2). Except for
the distribution of smoking and drinking status and diastolic
blood pressure, all variables listed in Table 2 differed
signiﬁcantly between persons with incident HF and those
without.
After a median follow-up time of 3.5 years (5th to 95th
percentile: 2.3–5.5 years), 470 incident HF cases were
present. Overall sex- and age-adjusted incidence of HF was
12.1 (95% CI, 11.0–13.2) per 1000 person-years. In persons
younger than 75 years, the sex-adjusted incidence rate was
9.8 (95% CI, 8.6–11.1) per 1000 person-years, while the sex-
adjusted incidence rate for HF in persons older than 75 years
was 15.3 (95% CI, 13.5–17.3) per 1000 person-years. The
sex-adjusted cumulative incidence per age group is shown in
Figure 2.
The Cox regression analysis, corrected for study, showed
that higher age, BMI, smoking, diabetes mellitus, history of
coronary artery disease, use of antihypertensive medication,
higher systolic blood pressure, heart rate, and serum crea-
tinine were signiﬁcantly associated with an increased risk of
HF onset. Hazard ratios for a 1-unit increase in risk factor are
given in Table 3.
Model Assessment
The AUC for discriminating HF risk based on our Cox model
was 0.706. After bootstrapping, we corrected the AUC for
overoptimism and obtained an AUC of 0.702. Observed
versus expected numbers of HF according to deciles of the 5-
year risk show good agreement (Grønnesby-Borgan v2 7.9;
P=0.54). Figure 3 shows the calibration of the Cox model by
plotting deciles of HF risk.
We assessed calibration among the individual studies.
Grønnesby-Borgan v2 statistics for PREDICTOR, Health ABC,
and PROSPER were 2.9 (P=0.97), 5.1 (P=0.83), and 16.2
(P=0.06), respectively. Figure 4 shows the observed versus
expected number of events for each individual study.
The risk function was externally validated using data from
ASCOT. In 13 121 participants (mean age 63.3 years, 23.0%
women), 191 HF events (HF hospitalization or death) occurred
over a median follow-up of 5.6 years (5th–95th percentile:
3.4–6.6). The AUC was 0.692 when we applied our risk
function to this cohort.
Sensitivity Analyses
We examined the effect of antihypertensive treatment on
incident HF in more detail by using speciﬁc classes of
antihypertensive treatment: b-blockers, RAAS inhibitors
(including angiotensin-converting enzyme inhibitors and
angiotensin II type 1 receptor blockers), vasodilators (calcium
channel blockers and a-blockers), and diuretics. Results
DOI: 10.1161/JAHA.116.005231 Journal of the American Heart Association 4
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(Table 4) show that RAAS inhibitors, diuretics, and vasodila-
tors were signiﬁcantly associated with risk of incident HF,
while use of b-blockers were not.
Heart Failure Risk Calculator
Figure S1 is a calculator to compute a person’s HF risk. Using
the calculator, we obtain an HF risk of 2.58% for a 71-year-old
woman, with a BMI of 26.4 kg/m2, nonsmoker, with diabetes
mellitus, no history of coronary artery disease, who needs to
use antihypertensive medication, with a systolic blood
pressure of 150 mm Hg, heart rate of 62 beats per minute,
and serum creatinine of 151.2 lmol/L. The calculation is
done as described below:
ðb1  ageþ b2  sexþ b3  body mass indexþ b4
 smokingþ b5  diabetes þ b6
 history of coronary artery diseaseþ b7
 antihypertensive treatmentþ b8
 systolic blood pressure þ b9  heart rateþ b10
 serum creatinineÞ
Table 2. Baseline Characteristics by Incident HF
All HF No HF
No. of patients 10 236 470 9766
Mean of characteristicsSD
Age, y 74.53.7 75.33.7 74.53.6§
BMI, kg/m2 26.94.4 27.74.7 26.84.3§
Systolic blood pressure, mm Hg 146.922.7 149.524.9 146.822.5‡
Diastolic blood pressure, mm Hg 79.912.3 79.114.1 80.012.2
Heart rate, beats per min 66.711.5 68.912.5 66.611.5§
Blood glucose, mmol/L 5.601.60 5.922.13 5.581.57§
Cholesterol, mmol/L 5.500.97 5.370.98 5.510.97†
LDL cholesterol, mmol/L 3.540.89 3.440.90 3.540.89*
HDL cholesterol, mmol/L 1.330.40 1.290.41 1.330.38*
Serum creatinine, lmol/L 96.227.7 106.642.0 95.826.7§
No. with characteristics, %
Women 5248 (51.3) 212 (45.1) 5036 (51.6)†
Smokers 2052 (20.1) 100 (21.3) 1952 (20.0)
Consume alcohol 5592 (54.6) 237 (50.4) 5355 (54.8)
Hypertension 6577 (64.3) 334 (71.1) 6243 (63.9)†
Diabetes mellitus 1299 (12.7) 90 (19.2) 1209 (12.4)§
History of cardiovascular disease 3701 (36.2) 254 (54.0) 3447 (35.3)§
History of coronary artery disease 2606 (25.5) 209 (44.5) 2397 (24.5)§
History of peripheral artery disease 257 (2.5) 25 (5.3) 232 (2.4)§
History of cerebrovascular incident 856 (8.4) 55 (11.7) 801 (8.2)†
Use of antihypertensive medication 6596 (64.4) 355 (75.5) 6241 (63.9)§
Use of ACEIs 1697 (16.6) 121 (25.7) 1576 (16.1)§
Use of calcium channel blockers 2345 (22.9) 159 (33.8) 2186 (22.4)
Use of diuretics 3372 (32.9) 192 (40.9) 3180 (32.6)‡
Use of b-blockers 2087 (20.4) 94 (20) 1993 (20.4)
Use of angiotensin receptor blockers 502 (4.9) 26 (5.5) 476 (4.9)
The study population includes data from the Health ABC (Health Aging and Body Composition), PREDICTOR (Valutazione della PREvalenza di DIsfunzione Cardiaca asinTOmatica e di
scompenso cardiac), and PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) studies. Data are reported as meanSD or number (percentage). ACEIs indicates angiotensin-
converting enzyme inhibitors; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Signiﬁcance for the comparison between patients developing heart failure (HF) and those not developing HF: *P≤0.05; †P≤0.01; ‡P≤0.001; §P≤0.0001.
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Value of the risk factor of the individual
Xp
i¼1
biXi¼ 0:0748ð71Þ0:149ð1Þþ0:0329ð26:4Þ
þ0:61ð0Þþ0:346 ð1Þþ0:914ð0Þþ0:503
ð1Þþ0:0089ð150Þþ0:0203ð62Þ
þ0:0050ð151:2Þ¼10:2242
Mean value of the risk factors
þ
Xp
i¼1
biXi ¼ 0:050 ð73:4Þ  0:019 ð0:50Þ þ 0:66
 ð0:11Þ þ 1:03 ð0:17Þ þ 0:53 ð0:52Þ
þ 0:018 ð137:0Þ þ 0:024 ð67:1Þ
þ 0:078 ð5:79Þ þ 0:0044 ð90:2Þ
¼ 10:2419
5-year estimated survival=S0(t)= 0.9738
p ¼ 1 S0ðtÞexpð
Pp
i¼1 biXi
Pp
i¼1 bi
XiÞ
¼ 1 0:9738expð10:224210:2419Þ ¼ 0:0258 ¼ 2:58%
Discussion
In this study, we developed a multivariable risk prediction tool
to be used in daily clinical practice. The developed risk
calculator estimates the risk of new-onset HF in older people.
Our stepwise approach identiﬁed several routinely available
risk factors such as smoking, blood pressure, heart rate,
diabetes mellitus, and creatinine levels, as well as nonmod-
iﬁable factors such as sex and age.
Risk Factors
The risk factors identiﬁed were in line with expectations and
have been previously shown to be associated with incident
HF.18–20 Older individuals had a higher risk for incident HF,
explained by the age-related cardiac structural and functional
changes. The Framingham Study showed that per decade, the
risk of HF increased by 24% in women and by 37% in men.21
Several studies examined the effect of smoking in older adults
Figure 3. Calibration is shown. Observed (open bar) vs
expected (solid bar) number of heart failure events across deciles
of 5-year heart failure risk.Figure 2. Sex-adjusted cumulative heart failure (HF) incidence
per age group.
Table 3. Hazard Ratios Relating HF Outcome to Risk Factors
Study Population (Health ABC, PREDICTOR, PROSPER)
Risk Factor Hazard Ratio 95% CI P Value
Female 0.86 0.71–1.04 0.12
Age, per y 1.08 1.05–1.11 <0.0001
BMI, per kg/m2 1.03 1.01–1.06 0.002
Smoking (0,1) 1.84 1.46–2.32 <0.0001
Diabetes mellitus (0,1) 1.41 1.12–1.79 0.004
History of coronary artery
disease (0,1)
2.49 2.06–3.01 <0.0001
Use of antihypertensive
medication (0,1)
1.65 1.33–2.06 <0.0001
Systolic blood pressure, per
mm Hg
1.009 1.005–1.013 <0.0001
Heart rate, per beats per min 1.02 1.01–1.03 <0.0001
Serum creatinine,
per lmol/L
1.005 1.004–1.006 <0.0001
Hazard ratios are expressed per 1-unit increase in continuous risk factors. All analyses
are corrected for study. Health ABC indicates Health Aging and Body Composition; HF,
heart failure; PREDICTOR, Valutazione della PREvalenza di DIsfunzione Cardiaca
asinTOmatica e di scompenso cardiac; PROSPER, Prospective Study of Pravastatin in the
Elderly at Risk.
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and found a higher risk for HF in both current and former
heavy cigarette smokers.22,23 Elevated systolic blood pres-
sure is associated with increased risk of cardiovascular events
and death in the general population.24 In older people and
high-risk patients, higher systolic blood pressure was a
consistent risk factor. Resting heart rate is another variable
with potential predictive capacity in HF and cardiovascular
disease development. A recent study showed that resting
heart rate was independently associated with incident HF in
men during follow-up and this association was found to be
signiﬁcant in men with both single and repeated heart rate
measurement over time.25 These ﬁndings are replicated in our
analyses as well. We also showed that diabetes mellitus were
associated with increased HF risk. Hyperglycemia and insulin
resistance are known to have unfavorable effects on the heart
by increasing left ventricular mass index and wall thickness
and promoting myocardial ﬁbrosis and left ventricular dys-
function, which may be caused by increased oxidative stress
and cardiac autonomic neuropathy.26,27 In fact, incident HF
was among the most frequent events among other cardio-
vascular events in recently published diabetes cardiovascular
outcome trials on new oral hypoglycemic drugs in patients
with type 2 diabetes mellitus.28–30 In addition, in a subgroup
of the Health ABC study, in persons without known diabetes
mellitus, glucose was a strong predictor of incident HF.31
Subsequently, serum creatinine was identiﬁed as a risk factor
for incident HF. Creatinine is widely used to measure kidney
function, and kidney damage has been associated with
increased HF risk.32 Our results further reveal that persons
who are taking antihypertensive treatment are at higher risk
for incident HF. Previous studies showed that treatment with
antihypertensive medication was associated with an
increased residual cardiovascular risk.33–36 It seems that
the cardiovascular risk associated with hypertension cannot
be totally diminished by intake of medication. Probably,
patients taking hypertensive treatment at entry already had a
Figure 4. Calibration per individual study. Observed (open bar) vs expected (solid bar) number of heart failure events across deciles of 5-year
risk for the Health ABC (Health Aging and Body Composition), PREDICTOR (Valutazione della PREvalenza di DIsfunzione Cardiaca asinTOmatica e
di scompenso cardiac), and PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) studies, which were used to develop the heart
failure risk function. ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) was used as an external validation cohort.
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higher cardiovascular risk proﬁle, independent of blood
pressure control. Looking into speciﬁc classes of antihyper-
tensive treatment, we identiﬁed vasodilators, diuretics, and
RAAS inhibitors as being associated with higher HF risk. This
counterintuitive observation might be explained by reverse
epidemiology: persons who need to take these drugs are most
likely the ones who are already at higher risk for HF. Indeed,
persons with symptoms of angina pectoris or previous
coronary heart disease, who already have an increased HF
risk, are often under treatment with vasodilators.37 Similarly,
persons with severe hypertension, treated with diuretics, are
at higher risk. Moreover, physicians might prescribe these
medications to patients with suspected HF, or with mild
symptoms, before the diagnosis of overt HF is made.
Prediction Models
Rather than assessing single risk factors, risk prediction
models allow the identiﬁcation of a broader segment of the
population. Previously, risk models have been developed to
predict HF risk, including mostly US and European cohorts.19
Most HF prediction models were described as mathematical
equations, with only 2 US studies providing a point-based risk
score.14,21 We provide an easy-to-use risk calculator in Excel
to allow simple risk calculation for clinicians and facilitate its
use in daily practice. Several HF prediction models assessed
the discriminatory ability of B-type natriuretic peptide or
N-terminal pro–B-type natriuretic peptide on top of traditional
risk factors.38–42 Overall, a modest improvement in discrim-
ination was observed.40–43 This does not mean that biomark-
ers could not be useful in further reﬁning the identiﬁcation of
at-risk patients. Adding biomarker information should be the
next step to further categorize persons initially identiﬁed at
high risk, based on our available clinical risk parameters. The
HOMAGE consortium remains dedicated to discovering
biomarkers that could lead to new insights and improve risk
stratiﬁcation, mechanistic proﬁling, and early detection of HF.
Data of the Health ABC study were previously used to develop
an HF risk score.14 We pooled the Health ABC data with data
from the European PREDICTOR and PROSPER studies, which
also include elderly people. Inclusion of both US and European
persons adds to the generalizability of the developed risk
score in elderly persons.
Limitations
Limitations of our study include the inability to systematically
distinguish between participants with incident HF according
to the type of left ventricular dysfunction (systolic versus
diastolic). Recently, a large study including 4 population-based
cohorts identiﬁed differences in risk factors predicting HF
with preserved ejection fraction and HF with reduced ejection
fraction.44 Although age, BMI, systolic blood pressure,
previous myocardial infarction, and antihypertensive treat-
ment were identiﬁed as risk factors for both HF subtypes,
male sex, smoking, left ventricular hypertrophy, left bundle
branch block, and diabetes mellitus were found to only predict
HF with reduced ejection fraction.20
Next, the diagnosis of HF is less clear and speciﬁc then, for
example, myocardial infarction. The HF end point in our cohort
was based on nonfatal HF hospitalization, which implicates
that HF diagnosed at an outpatient clinic or by general
practitioners was not included. Moreover, differences in HF
hospitalization deﬁnition between the cohorts occur due to
factors such as hospital admissions policy, treating physi-
cians, adherence to guidelines for therapy, and support by
dedicated HF nurses.
Finally, our risk score was developed in elderly patients at
risk for vascular disease. Particularly in this population,
aggravating factors related to rehospitalizations such as
intercurrent infections, atrial ﬁbrillation, anemia, or hyperthy-
roidism could play a role. We did not take into account these
factors, since we focused on ﬁrst hospitalization for HF and
aimed to provide a risk score based on readily available
clinical risk factors, to facilitate its use in daily practice.
Table 4. Hazard Ratios Relating HF Outcome to Risk Factors,
Including Classes of Antihypertensive Treatment
Study Population (Health ABC, PREDICTOR, PROSPER)
Risk Factor
Hazard
Ratio 95% CI P Value
Female 0.87 0.71–1.05 0.15
Age, per y 1.08 1.05–1.11 <0.0001
BMI, kg/m2 1.03 1.01–1.05 0.007
Smoking (0,1) 1.84 1.46–2.32 <0.0001
Diabetes mellitus (0,1) 1.36 1.07–1.72 0.012
History of coronary
artery disease (0,1)
2.52 2.08–3.06 <0.0001
Use of b-blockers (0,1) 1.03 0.81–1.30 0.84
Use of RAAS inhibitors (0,1) 1.55 1.27–1.90 <0.0001
Use of vasodilators (0,1) 1.35 1.13–1.67 0.003
Use of diuretics (0,1) 1.37 1.13–1.67 0.002
Systolic blood pressure,
per mm Hg
1.009 1.005–1.013 <0.0001
Heart rate, per beats per min 1.02 1.01–1.03 <0.0001
Serum creatinine, per lmol/L 1.005 1.004–1.006 <0.0001
Hazard ratios are expressed per 1-unit increase in continuous risk factors. All analyses
are corrected for study; the analysis in the patient cohort was further corrected for
randomization group. Health ABC indicates Health Aging and Body Composition; HF,
heart failure; PREDICTOR, Valutazione della PREvalenza di DIsfunzione Cardiaca
asinTOmatica e di scompenso cardiac; PROSPER, Prospective Study of Pravastatin in the
Elderly at Risk; RAAS, renin-angiotensin-aldosterone system.
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Strengths
The strengths of our study are that we included persons from
well-characterized populations, with an adequate follow-up
period. Risk factors included are routinely available and our
estimates are derived from a large sample. The risk function
calculator is easy to use by clinicians or nurses and could be
useful as a tool in risk factor modiﬁcation screening within a
public health or clinical setting. We assessed the validity of
our HF risk model in the ASCOT cohort, showing good
discrimination and calibration.
According to a recent systematic review, there are no
recommendations in current guidelines for using risk predic-
tion models for HF or studies assessing the effect of such
models in routine clinical practice.19 Research into a practical
application of our risk prediction scores remains necessary to
give a deﬁnitive answer to whether improvement of outcome
can be expected by using the risk tool. Indeed, for example,
collaborative care in patients at risk for developing HF based
on B-type natriuretic peptide screening reduced the combined
rates of left ventricular systolic dysfunction, diastolic dys-
function, and HF.45
Conclusions
An increase in HF over the next decades will translate to more
than a 200% increase in direct medical costs of care.46 To
mitigate mortality and healthcare costs, effective prevention
of HF that can offer early correction of predisposing
conditions and risk factors in susceptible persons is required.
Our HF risk model allows reliable identiﬁcation of high-risk
populations, contributing to a more targeted and cost-
effective implementation of preventive measures for HF.
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